GW
MRNA icon

GW & Wade’s Moderna MRNA Stock Holding History

GW & Wade’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$591K Sell
5,943
-571
-9% -$48K 0.02% 275
2023
Q3 		$673K Buy
6,514
+1,970
+43% +$220K 0.03% 245
2023
Q2 		$552K Sell
4,544
-273
-6% -$36.4K 0.02% 263
2023
Q1 		$740K Buy
4,817
+85
+2% +$14K 0.03% 228
2022
Q4 		$850K Buy
4,732
+389
+9% +$63.6K 0.03% 210
2022
Q3 		$514K Buy
4,343
+293
+7% +$44.5K 0.03% 238
2022
Q2 		$579K Buy
4,050
+772
+24% +$110K 0.03% 236
2022
Q1 		$565K Buy
3,278
+34
+1% +$5.72K 0.02% 231
2021
Q4 		$824K Sell
3,244
-1,736
-35% -$508K 0.04% 201
2021
Q3 		$1.92M Sell
4,980
-2,560
-34% -$944K 0.09% 141
2021
Q2 		$1.77M Buy
7,540
+802
+12% +$143K 0.09% 143
2021
Q1 		$882K Buy
6,738
+442
+7% +$64K 0.05% 175
2020
Q4 		$658K Buy
6,296
+231
+4% +$23.4K 0.04% 170
2020
Q3 		$429K Buy
6,065
+1,765
+41% +$123K 0.03% 163
2020
Q2 		$276K Buy
+4,300
New +$235K 0.02% 200

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GW & Wade's MRNA Position: Q4 2023 in Review

GW & Wade reduced its Moderna (MRNA) stake by 8.8% in Q4 2023, selling an estimated $48K and leaving 5,943 shares worth $591K. The position accounts for 0.02% of the portfolio, ranked #275.

GW & Wade first reported a position in MRNA in Q2 2020 and has held it in 15 quarters since. The position peaked at $1.92M in Q3 2021. 885 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • GW & Wade held 5,943 shares of Moderna worth $591K as of Q4 2023.
  • GW & Wade sold 571 Moderna shares in Q4 2023, an estimated $48K.
  • Moderna made up 0.02% of GW & Wade's portfolio in Q4 2023, its #275 holding.
  • GW & Wade first reported a position in Moderna in Q2 2020 and has held it in 15 quarters since.
  • GW & Wade's Moderna position peaked at $1.92M in Q3 2021.
  • 885 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on GW & Wade's 13F filing for Q4 2023, filed 8 Feb 2024.